

Study or Subgroup	Placebo/MTX		JAKI+MTX		Weight	Risk Ratio	Risk Ratio
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI
8.5.1 Filgotinib 25mg + MTX							
Westhovens 2017	0	32	0	34		Not estimable	
Subtotal (95% CI)		32		34		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
8.5.2 Filgotinib 50mg + MTX							
Westhovens 2017	0	32	0	78		Not estimable	
Subtotal (95% CI)		32		78		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
8.5.3 Filgotinib 100mg + MTX							
Westhovens 2017	0	32	0	84		Not estimable	
Subtotal (95% CI)		32		84		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
8.5.4 Filgotinib 200mg + MTX							
Westhovens 2017	0	32	0	38		Not estimable	
Subtotal (95% CI)		32		38		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
Total (95% CI)		128		234		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
Test for subgroup differences: Not applicable							

